On 5/10/24, Revance Therapeutics Inc (NASDAQ: RVNC) stock suffered a major decline of -22.6%, closing at $3.32. Moreover, trading volume in this decline was exceptionally high at 415% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -11.9% during the last week.
Current PriceTarget Research Rating
RVNC’s future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to be a modest Value Eraser.
Revance Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment